Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
2018; Massachusetts Medical Society; Volume: 378; Issue: 1 Linguagem: Inglês
10.1056/nejmoa1703327
ISSN1533-4406
AutoresKeith Sullivan, Ellen Goldmuntz, Lynette Keyes-Elstein, Peter A. McSweeney, Ashley Pinckney, Beverly Welch, Maureen D. Mayes, Richard A. Nash, Leslie J. Crofford, Barry Eggleston, Sharon Castina, Linda M. Griffith, Julia Goldstein, Dennis Wallace, Oana Craciunescu, Dinesh Khanna, Rodney J. Folz, Jonathan Goldin, E. William St. Clair, James R. Seibold, Kristine Phillips, Shin Mineishi, Robert W. Simms, Karen K. Ballen, Mark H. Wener, George E. Georges, Shelly Heimfeld, Chitra Hosing, Stephen J. Forman, Suzanne Kafaja, Richard M. Silver, Leroy Griffing, Jan Storek, Sharon LeClercq, Richard Brasington, Mary Ellen Csuka, Christopher Bredeson, Carolyn A. Keever-Taylor, Robyn T. Domsic, M. Bashar Kahaleh, Thomas A. Medsger, Daniel E. Furst,
Tópico(s)Dermatologic Treatments and Research
ResumoDespite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions of cyclophosphamide in patients with scleroderma.
Referência(s)